A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy
Status:
Recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to compare the change in pain intensity during treatment
with a CGRP monoclonal antibody (eptinezumab) compared with placebo treatment in patients
with painful diabetic polyneuropathy (DPN).